Subscribe to eTOC

Atogepant Reduces Number of Mean Monthly Migraines

Neurology Today At the American Academy of Neurology Annual Meeting: People with migraine who took atogepant, an orally administered calcitonin gene-related peptide receptor antagonist, had an average of three to four fewer migraines each month. Neurology Today Editor-in-Chief Joseph E. Safdieh interviews Jessica Ailani, MD, FAAN, director of MedStar Georgetown Headache Center and professor of clinical neurology in the department of neurology at Medstar Georgetown University in Washington, DC, about the clinical implications of the research. Read the full report with Neurology Today At the Meetings: https://bit.ly/3dBUNvm.


Recent Videos

Show: